Page 265 - The Vasculitides Volumes 2

Overview of the Treatment of Primary Systemic Vasculitis 241

[71] Loock, J., Henes, J., Kötter, I., et al. Treatment of refractory giant cell arteritis with
cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin. Exp.
Rheumatol. 2012; 30(Suppl. 70):S70-S76.

[72] De Silva, M., Hazleman, B. L. Azathioprine in giant cell arteritis/polymyalgia
rheumatica: a double-blind study. Ann. Rheum. Dis. 1986; 45:136-138.

[73] Le Guennec, P., Dromer, C., Sixou, L., et al. [Treatment of Horton disease. Value of
synthetic antimalarials. Apropos of a retrospective study of 36 patients. Rev. Rheum.
Ed. Fr. 1994; 61:485-490.

[74] Schaufelberger, C., Möllby, H., Uddhammar, A., et al. No additional steroid-sparing
effect of cyclosporine A in giant cell arteritis. Scand. J. Rheumatol. 2006; 35:327-329.

[75] Oliveira, F., Butendieck, R. R., Ginsburg, W. W., et al. Tocilizumab, an effective
treatment for relapsing giant cell arteritis. Clin. Exp. Rheumatol. 2014; 32(Suppl. 82):
S76-S78.

[76] Unizony, S. H., Dasgupta, B., Fisheleva, E., et al. Design of the tocilizumab in giant
cell arteritis trial. Int. J. Rheumatol. 2013; Apr. 7 [Epub. ahead of print].

[77] Nesher, G., Berkun, Y., Mates, M., et al. Low-dose aspirin and prevention of cranial
ischemic complications in giant cell arteritis. Arthritis Rheum. 2004; 50:1332-1337.

[78] Lee, M. S. 1., Smith, S. D., Galor, A., Hoffman, G. S. Antiplatelet and anticoagulant
therapy in patients with giant cell arteritis. Arthritis Rheum. 2006; 54:3306-3309.

[79] Liang, P., Hoffman, G. S. Advances in the medical and surgical treatment of Takayasu
arteritis. Curr. Opin. Rheumatol. 2005; 17:16-24.

[80] Hoffman, G. S., Merkel, P. A., Brasington, R. D., et al. Anti-tumor necrosis factor
therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004; 50:
2296-2304.

[81] Molloy, E. S., Langford, C. A., Clark, T. M., et al. Anti-tumour necrosis factor therapy
in patients with refractory Takayasu arteritis: long-term follow-up. Ann. Rheum. Dis.
2008; 67:1567-1569.

[82] Mekinian, A., Néel, A., Sibilia, J., et al. Efficacy and tolerance of infliximab in
refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) 2012;
51:882-886.

[83] Comarmond, C., Plaisier, E., Dahan, K., et al. Anti TNF-? in refractory Takayasu
arteritis: cases series and review of the literature. Autoimmune Rev. 2012; 11:678-684.

[84] Hoyer, B. F., Mumtaz, I. M., Loddenkemper, K., et al. Takayasu arteritis is
characterized by disturbances of B cell homeostasis and responds to B cell depletion
with rituximab. Ann. Rheum. Dis. 2012; 71:75-79.

[85] Seitz, M., Reichenbach, S., Bonel, H. M., et al. Rapid induction of remission in large
vessel vasculitis by IL-6 blockade. A case series. Swiss. Med. Wkly. 2011 Jan. 17; 141:
w13156.

[86] Perera, A. H., Youngstein, T., Gibbs, R. G., et al. Optimizing the outcome of vascular
intervention for Takayasu arteritis. Br. J. Surg. 2014; 101:43-50.

[87] Park, H. S., Do, Y. S., Park, K. B., et al. Long term results of endovascular treatment in
renal arterial stenosis from Takayasu arteritis: angioplasty versus stent placement. Eur.
J. Radiol. 2013; 82:1913-1918.

[88] Saadoun, D., Lambert, M., Mirault, T., et al. Retrospective analysis of surgery versus
endovascular intervention in Takayasu arteritis: a multicentre experience. Circulation
2012; 125:813-819.

Complimentary Contributor Copy